Though executives claimed that inking deals and de-risking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term.
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
Michel Vounatsos, Biogen’s CEO since 2017, will be replaced as the company “substantially” eliminates the commercial workforce around Aduhelm, which has generated paltry sales in the face of resistance from insurers and doctors.
Business trends normalized in the first quarter, with less of a boost from COVID-19 tailwinds for the Rhode Island-based company.
The investment from Banner will help Atlas scale and “grow into a larger national partner for other health systems,” the companies announced Tuesday.
The results surprised Johns Hopkins University researchers, who said it contrasted with earlier findings showing an inverse link between socioeconomic status and use of telemedicine in the pandemic.
Some doctors listed in managed care provider network directories didn’t file any Medicaid claims over the course of a year, according to new research published in Health Affairs.
Many patients returned for nonurgent procedures and other non-COVID-19 care, especially outpatient, that had been previously delayed, according to a Kaufman Hall report.
Nurses will return to work Tuesday after ratifying a deal on new contracts that include measures to better retain and recruit nursing staff amid shortages worsened by the pandemic, according to the union.
CMS Administrator Chiquita Brooks-LaSure said the controversial plan would provide coverage to fewer people and no longer complies with federal law and other policies.